Introduction
============

Thalassemia is one of the most common single gene inheritance diseases in the world.^\[[@R1]\]^ It is caused by the interruption of *α*- or *β*-globin chain synthesis, leading to an imbalance in the ratio of α/non-α chains. -*α*^3.7^, -*α*^4.2^, and \--^SEA^ are the most common *α*-thalassemia (*α*-thal) deletions found in China.^\[[@R2]\]^ The overall prevalence of \--^SEA^, -*α*^3.7^, and -*α*^4.2^ was 68.06%, 25.0%, and 2.78%, respectively, in Chengdu, Sichuan, China.^\[[@R3]\]^ In 2005, Wang *et al*^\[[@R4]\]^ found a rare rearrangement of the α-globin gene cluster, HongKong*αα* (HK*αα*) allele, which contains both -*α*^3.7^ and *ααα*^anti-4.2^ crossover junctions. The -*α*^3.7^ and *ααα*^anti-4.2^ fragments are located on the same chromosome as HK*αα*, whereas on two chromosomes, it is -*α*^3.7^/*ααα*^anti-4.2^. However, both HK*αα* and -*α*^3.7^/*ααα*^anti-4.2^ are misdiagnosed as -*α*^3.7^/*αα* by the current conventional thalassemia detection methods.

The HK*αα* allele contains neither deletion nor triplication, and carriers of this allele are unlikely to suffer any deleterious effects. Moreover, there were no differences between HK*αα*/\--^SEA^ and -*α*^3.7^/*αα* in erythrocyte parameters or hemoglobin electrophoresis results.^\[[@R4],[@R5]\]^ Once HK*αα* is misdiagnosed as the -*α*^3.7^ deletion, and the patient\'s spouse is \--^SEA^/*αα*, while unnecessary amniocentesis is required for a clear diagnosis, increasing the risk of abortion and economic burden, causing psychological stress.

The clinical manifestations of -*α*^3.7^/*ααα*^anti-4.2^ are similar to HK*αα* in theory. However, as the genotype is rare, the number of reports is small.^\[[@R6]\]^ When the patient\'s spouse is a carrier of *β*-thalassemia (*β*-thal), their offspring have a 1/4 probability of *ααα*^anti-4.2^ and *β*-thal coinheritance. *ααα* triploid aggravates the imbalance of *α*/*β* due to the increase in the *α*-globin chain, which aggravates the clinical manifestation of *β*-thalassemia.^\[[@R7]--[@R11]\]^ Therefore, when -*α*^3.7^/*ααα*^anti-4.2^ is misdiagnosed as -*α*^3.7^/*αα*, the genetic probability of moderate to severe thalassemia may be misjudged by clinicians, and may exacerbate the birth of anemic children.

At present, routine testing for thalassemia cannot detect HK*αα* and -*α*^3.7^/*ααα*^anti-4.2^. Gap-polymerase chain reaction (Gap-PCR) and reverse dot blot (RDB) assays are widely used to detect the common *α*-thal and *β*-thal mutations.^\[[@R12],[@R13]\]^ The HK*αα* allele and some additional genotypes (HK*αα*/\--^SEA^, HK*αα*/-*α*^4.2^, and HK*αα*/*α*^CS^*α*) formed by HK*αα* can be detected by multicolor melting curve analysis with real-time PCR.^\[[@R14]\]^ However, none of the three methods can detect triplication of the *α*-globin gene. Nested PCR is a cost-effective way to detect the HK*αα* allele, but it cannot identify additional genotypes. Sequencing is well suited to the detection of small sequence changes and is less well adapted for detecting structural variants.^\[[@R15]\]^ Multiplex ligation-dependent probe amplification (MLPA) is a useful technique for detecting and identifying copy number variation (deletions/duplications) in any region of the genome.^\[[@R16],[@R17]\]^ This technique has been applied to detect the *HBA* and *HBB* gene.^\[[@R18]--[@R21]\]^ Xie *et al*^\[[@R22]\]^ detected HK*αα*/*αα* with MLPA. However, when the balanced translocation of chromosomes coexists in samples, the results of MLPA are incorrect. Some genotypes, such as -*α*^4.2^/*ααα*^anti-4.2^ and -*α*^3.7^/*ααα*^anti-3.7^, may be diagnosed in normal subjects by this technology.

Therefore, nested PCR combined with MLPA was used to analyze the genotypes of *ααα*^anti-4.2^ and HK*αα* in patients with -*α*^3.7^ deletion thalassemia, and to ascertain whether it coexists with other genotypes of thalassemia.

Methods
=======

Ethical approval
----------------

The study was followed the principles of *Declaration of Helsinki* and approved by the Institutional Review Committee of Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People\'s Hospital (No. 2019-1). Informed consent was obtained from each patient and their family members before genetic testing was performed.

Samples and hematologic analysis
--------------------------------

A total of 5488 peripheral blood samples for thalassemia testing were collected from July 2017 to October 2019 in Sichuan Provincial People\'s Hospital, China. Of these, 1461 (26.62%) were male and 4027 (74.38%) female. The patients were in the age range of 2 month-60 years (27.72±10.53 years). The hematological parameters of the samples were determined by an automatic analyzer XN-10 (Sysmex Corporation, Kobe, Japan). A capillary electrophoresis device (Capillarys; Sebia, Montpellier, France) was used for hemoglobin electrophoresis analysis.

Analysis of common thalassemia mutations by Gap-PCR and RDB
-----------------------------------------------------------

Genomic DNA was extracted from peripheral blood. Single-tube multiplex Gap-PCR was used to test the four *α*-globin gene deletion (-*α*^3.7^, -*α*^4.2^, \--^SEA^, and \--^THAI^) (Shenzhen Yishengtang Biological Enterprise Co., Ltd, Shenzhen, China). All DNA samples with the -*α*^3.7^ deletion were collected.

The RDB assay was used for three common non-deletional *α*-thal mutations (Hb Constant Spring \[Hb CS\] *HBA2*: c.427T\>C, Hb Quong Sze \[Hb QS\] *HBA2*: c.377T\>C, and Hb Westmead \[Hb WS\] *HBA2*: c.369122C\>G\] and 17 known Chinese *β*-thal mutations^\[[@R23]\]^ (Shenzhen Yishengtang Biological Enterprise Co., Ltd).

Analysis of the genotypes of *ααα*^anti-4.2^ and HK*αα* allele
--------------------------------------------------------------

The *ααα*^anti-4.2^ junction was assessed by the anti-4.2 multiplex-PCR assay for samples diagnosed as -*α*^3.7^. All primers were used to detect the HK*αα* allele \[Table [1](#T1){ref-type="table"}\].^\[[@R6],[@R13]\]^ Each 20 μL reaction contained the following: 10 ng/μL DNA, 1× GC Buffer I, 0.4 mmol/L dNTP, 0.3 μmol/L anti-4.2-F, 0.3 μmol/L anti-4.2-R, 0.15 μmol/L LIS1-2.5-F, 0.15 μmol/L LIS1-2.5-R, 0.05 IU/μL Takara LA-Taq (Takara Bio, Shiga, Japan). Double-distilled water was added to a volume of 20 μL. The PCR procedure was as follows: 95° C for 1 min initially, followed by 35 cycles of 94° C for 30 s and 68° C for 3 min, then a final 3 min at 68° C.

###### 

Primers for *ααα*^anti-4.2^ triplication and HK*αα* allele.

![](cm9-133-1175-g001)

Two-round nested PCR was carried out in samples with both -α^3.7^ and ααα^anti-4.2^ \[Figure [1](#F1){ref-type="fig"}\]. The first-round PCR amplified a DNA segment from X1 to Z1 boxes and a DNA segment for internal quality control. Each 20-μL reaction contained the following: 10 ng/μL DNA, 1× GC Buffer I, 0.4 mmol/L dNTP, 0.4 μmol/L L-anti-4.2-F, 0.4 μmol/L L-*α*3.7-R, 0.1 μmol/L LIS1-2.5-F, 0.1 μmol/L LIS1-2.5-R, 0.05 IU/μL Takara LA-Taq, and double-distilled water was added to a volume of 20 μL. The PCR procedure was as follows: 95° C for 1 min initially, followed by 35 cycles of 94° C for 30 s and 68° C for 5 min, then a final 3 min at 68° C.

![The strategy to confirm HongKong*αα* (HK*αα*) allele. For screening the HK*αα* allele, anti-4.2 multiplex polymerase chain reaction (PCR) amplifies an ∼1.7 kb fragment flanked by X1/X2 hybrid box using primers anti-4.2-F and anti-4.2-R. A two-round nested PCR strategy to confirm the presence of the HK*αα* allele. The first-round PCR amplifies ∼4.0 and ∼4.5 kb segments flanked by the X1 and Z1 boxes using primers L-anti-4.2-F and L-*α*3.7-R when HK*αα*/*αα* is present; the second-round PCR detects an ∼1.5 kb amplification fragment using primers AT4.2-F and AT4.2-R in the presence of the X1/X2 hybrid box (ie, the *ααα*^anti-4.2^ junction fragment). F: Forward; R: Reverse.](cm9-133-1175-g002){#F1}

The second-round PCR was used to amplify the *ααα*^anti-4.2^ duplication. For general amplification success, the LIS1-2.0 primers were also used as the internal quality control. The primers used in the nested PCR except for LIS1-2.5 and LIS1-2.0 primers are labeled in Figure [1](#F1){ref-type="fig"}. Each 20-μL reaction contained the following: 1 μL of the first-round PCR products diluted 1600 times as template, 0.4 mmol/L MgCL~2~, 1× EX Buffer (Mg^2+^ free), 0.4 mmol/L dNTP, 0.3 μmol/L AT4.2-F, 0.3 μmol/L AT4.2-R, 0.05 μmol/L LIS1-2.0-F, 0.05 μmol/L LIS1-2.0-R, and 0.05 IU/μL Takara EX Taq, and double-distilled water was added to a volume of 20 μL. The PCR procedure was as follows:95°C for 1 min initially, followed by 35 cycles of 95°C for 30 s, 56°C for 45 s, and 72°C for 60 s, then a final 3 min at 72°C.

Assessment of the copy number of the *HBA* gene by MLPA
-------------------------------------------------------

For samples carrying both -*α*^3.7^ and *ααα*^anti-4.2^, MLPA analysis was carried out using the SALSA MLPA KIT HBA140-C1 kit (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer\'s instructions. Three wild-type subjects were collected as references, and three common *α*-thal deletions (-*α*^3.7^/*αα*, -*α*^4.2^/*αα*, and \--^SEA^/*αα*) were used as positive controls of the *α*-globin gene cluster for MLPA. In short, the genomic DNA was denatured and hybridized with SALS-MLPA probes specific to the *α*-globin gene cluster. After ligation, PCR was performed using primers specific to the probes. The amplification results were analyzed on an ABI PRISM 3730 (Applied Biosystems, Foster City, CA, USA) Genetic Analyzer. The data were analyzed by coffalyser.net (MRC-Holland).

Statistical analysis
--------------------

The statistical software SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was applied for statistical analysis. Fisher\'s exact test was used to detect a statistically significant difference between the Gap-PCR and Gap-PCR combined with nested PCR and MLPA in detecting HK*αα* allele. Statistical significance was set as *P* \< 0.05.

Results
=======

Identification of thalassemia mutations by Gap-PCR and RDB assays
-----------------------------------------------------------------

Total 2544 cases were identified as thalassemia in 5488 peripheral blood samples. The results showed that *α*, *β*, and *αβ* compound thalassemia were identified in 1190 (46.78%), 1286 (50.55%), and 68 (2.67%) cases, respectively. A total of 227 samples from thalassemia patients were identified as -*α*^3.7^/*αα* by Gap-PCR. The other two patients were suspected to be HKαα carriers due to the presence of three bands (2.0, 1.7, and 1.2/1.4 kb, respectively) in the electrophoresis study.

Analysis of the genotypes of *ααα*^anti-4.2^ and the HK*αα* allele
------------------------------------------------------------------

Of the 229 patients who were identified as -α^3.7^/αα or suspected to be HKαα carriers, 20 patients were identified as HK*αα* carriers, and one patient was identified as a -*α*^3.7^/*ααα*^anti-4.2^ carrier by two-round nested PCR and MLPA, including 15 patients of HK*αα*/*αα*, three patients of HK*αα*/*αα* and *β*-thalassemia coinheritance, one patient with HK*αα*/\--^SEA^, one patient with HK*αα*/-*α*^4.2^ and *β*-thalassemia coinheritance, and one patient with -*α*^3.7^/*ααα*^anti-4.2^ and *β*-thalassemia coinheritance. The phenotypes and genotypes of the cases carrying the -*α*^3.7^ deletion and *ααα*^anti-4.2^ duplication are summarized in Table [2](#T2){ref-type="table"}. The interpretation of the PCR and MLPA results is shown in Table [3](#T3){ref-type="table"}.

###### 

The phenotype, genotype of cases carrying the -*α*^3.7^ and *ααα*^anti-4.2^.
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###### 

Interpretation of PCR and MLPA results.
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Comparison between Gap-PCR and the combination of Gap-PCR, nested PCR and MLPA in detecting HKαα allele
-------------------------------------------------------------------------------------------------------

There was a significantly difference between Gap-PCR and Gap-PCR combined with nested PCR and MLPA in detecting HK*αα* (*P* \< 0.05) \[Table [4](#T4){ref-type="table"}\]. Of the 229 patients, two patients were suspected of carrying HK*αα* by Gap-PCR. Gap-PCR combined with nested PCR and MLPA found that 21 patients were HK*αα* carriers or -*α*^3.7^/*ααα*^anti-4.2^. The error rate of diagnosis was 9.17% (21/229) by Gap-PCR in -*α*^3.7^ deletion.

###### 

Comparison of Gap-PCR and Gap-PCR combined with nested PCR and MLPA in detecting HK*αα*.

![](cm9-133-1175-g005)

Discussion
==========

In a clinical test, -*α*^3.7^/*αα*, HK*αα*/*αα*, HK*αα*/-*α*^3.7^, HK*αα*/*ααα*^anti-4.2^, HK*αα*/*ααα*^anti-3.7^, and -*α*^3.7^/*ααα*^anti-4.2^ may be misdiagnosed as -*α*^3.7^/*αα*. Different genotypes may lead to different clinical phenotypes. According to the literature, there is a considerable difference in the carrier frequency of HK*αα* in different geographical populations, and the carrying rate is about 0.07% to 2.27%.^\[[@R5],[@R24]\]^ In this study, of the 229 patients, 20 patients were identified as HK*αα* carriers, and one patient was identified as -*α*^3.7^/*ααα*^anti-4.2^ by two-round nested PCR and MLPA. The frequency of HK*αα* allele was as high as 8.81% among the -*α*^3.7^ carriers. The error rate of diagnosis is 9.17% (21/229) by Gap-PCR in -*α*^3.7^ deletion. Thus, to obtain a more accurate diagnosis and treatment, it was necessary to distinguish -*α*^3.7^ from HK*αα* and -*α*^3.7^/*ααα*^anti-4.2^.

In this study, when people were diagnosed as carriers of -*α*^3.7^, anti-4.2 multiplex-PCR was adopted to determine whether to continue supplementary experiments. However, HK*αα*/*αα*, HK*αα*/*ααα*^anti-4.2^, HK*αα*/*ααα*^anti-3.7^, HK*αα*/HK*αα*, and HK*αα*/-*α*^3.7^ could not be discerned from each other by Gap-PCR, anti-4.2 multiplex-PCR or nested PCR \[Table [3](#T3){ref-type="table"}\]. MLPA analysis was used to determine the number of copies of the *HBA* gene. However, when there are balanced translocations of chromosomes in specimens, they could not be correctly assessed by MLPA \[Figure [2](#F2){ref-type="fig"}C\]. In addition, MLPA is unable to determine whether deletions and duplications are located on the same chromosome. Thus, HK*αα*/*αα* could not be distinguished from -*α*^3.7^ /*ααα*^anti-4.2^ \[Figure [2](#F2){ref-type="fig"}A\]. Therefore, in this study, nested PCR was performed to detect the HK*αα* allele, and MLPA analysis was not only used to ensure the results of the nested PCR but also to find extra deletions or duplications. Thus, these two techniques could aid and verify each other \[Figure [2](#F2){ref-type="fig"}\].

![The analysis by multiplex ligation-dependent probe amplification (MLPA) integrating with nested polymerase chain reaction (PCR) (MRC-Holland, Amsterdam, The Netherlands). The left images were the results by MLPA, and the right images were the results by gap-PCR (Gap-PCR), anti-4.2 multiplex-PCR, and nested PCR. The *y*-axis represented the ratio signal as compared to the normal control (ratio 1); on the *x*-axis, the MLPA-probe numbers were shown on the figure. (A) HK*αα*/*αα* or -*α*^3.7^/*ααα*^anti-4.2^; (B) HK*αα*/\--^SEA^; (C) HK*αα*/-*α*^4.2^. HK*αα*: HongKong*αα*.](cm9-133-1175-g006){#F2}

All parameters were normal except for patients 2, 7, 10, 11, 12, 16, and 19. They might have been caused by the coinheritance of *β*-thal, -*α*^4.2^, or \--^SEA^ deletions. The other patients were HK*αα* heterozygotes, of which patient 7 showed obvious small-cell hypochromic anemia, which was confirmed by clinical analysis and combined with iron deficiency anemia. The hematological parameters of the other patients were almost normal, which was consistent with the results of Wang *et al*^\[[@R4]\]^ and Wu *et al*.^\[[@R24]\]^ Patient 16 is -*α*^3.7^/*ααα*^anti-4.2^ combined with *β*^IVS-2-654^/*β*^N^, which is rarer than HK*αα*. After testing, the patient\'s spouse was found to have a normal genotype, and their offspring have a 1/4 probability of -*α*^3.7^/*αα* complex *β*^N^/*β*^N^, 1/4 probability of -*α*^3.7^/*αα* complex *β*^N^/*β*^IVS-2-654^, 1/4 probability of *αα*/*ααα*^anti4.2^ complex *β*^N^/*β*^N^, and 1/4 probability of *αα*/*ααα*^anti-4.2^ complex *β*^N^/*β*^IVS-2-654^. The *αα*/*ααα*^anti4.2^ complex *β*^N^/*β*^IVS-2-654^ genotype can aggravate the clinical manifestations of *β*-thal. Therefore, genetic counseling should be carried out during pregnancy.

At present, there is no gold standard for testing the accurate genotypes of HK*αα* carriers as a reference. Thus we did not determine precise rates of this combination. In addition, samples of HK*αα*/*ααα*^anti-4.2^, HK*αα*/*ααα*^anti-3.7^, and HK*αα*/HK*αα* have not yet been collected. So, more samples should be collected and tested to confirm the findings of our study.

Generally, patients carrying the -*α*^3.7^ deletion of thalassemia must undergo screening for the *ααα*^anti-4.2^ and HK*αα* genotypes because of the high carrier frequency. Using nested PCR combined with MLPA can reduce the misdiagnosis rate of the HKαα allele and -*α*^3.7^/*ααα*^anti-4.2^ and enable more accurate genetic counseling.

Funding
=======

This work was supported by a grant from the Department of Science and Technology of Sichuan province, China (No. 30504010332).

Conflicts of interest
=====================

None.

**How to cite this article:** Chen DM, Ma S, Tang XL, Yang JY, Yang ZL. Diagnosis of the accurate genotype of HKαα carriers in patients with thalassemia using multiplex ligation-dependent probe amplification Combined with nested polymerase chain reaction. Chin Med J 2020;133:1175--1181. doi: 10.1097/CM9.0000000000000768
